A) Chemical structure of a KRAS inhibitor of the quinazoline chemotype designated “1.”
B) The crystal structure of mutant KRAS G12C in complex with compound 1 and GDP.
C) A dose titration with compound 1 shows inhibition of KRAS effector signaling through the MAPK pathway.